Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Microsatellite-stable (MSS) colorectal cancer (CRC) has shown poor response to checkpoint blockade immunotherapy. Here, the authors show that the combination of oxaliplatin with anti-PDL1 mAb is specifically efficient in the treatment of MSS CRC.
Guardado en:
Autores principales: | , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0515a6d971844b1e8f9a10f726dac7a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|